Eli Lilly and Co. (NYSE:LLY) now has added a third set of data aiming to show that inhibition of CETP is a viable treatment strategy for dyslipidemia. Lilly's first Phase II data for evacetrapib, released last week, show the highest dose more than doubled HDL while simultaneously lowering LDL, similar to data for anacetrapib from Merck & Co. Inc. (NYSE:MRK). A third cholesteryl ester transfer protein inhibitor, dalcetrapib from Roche (SIX:ROG; OTCQX:RHHBY), has shown an increase in HDL but not a decrease in LDL.

"It looks like anacetrapib and evacetrapib are twins," Eliot Brinton, a lipidologist and director